Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT01804400
- Locations
- 🇩🇪
Novartis Investigative Site, Hannover, Germany
Evaluation Montelukast in the Treatment of Status Asthmaticus
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Corrie Fletcher
- Target Recruit Count
- 100
- Registration Number
- NCT01770899
- Locations
- 🇺🇸
Advocate Children's Hospital Oak Lawn, Oak Lawn, Illinois, United States
Roflumilast Plus Montelukast in Adults With Severe Asthma
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01765192
Open-label Study of the Effects of Montelukast in Patients With Chronic Cough
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Association Asthma, Bulgaria
- Target Recruit Count
- 14
- Registration Number
- NCT01754220
- Locations
- 🇧🇬
Clinic of Allergy and Asthma, University Hospital "Alexandrovska", Sofia, Bulgaria
A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Pulmagen Therapeutics
- Target Recruit Count
- 248
- Registration Number
- NCT01730027
- Locations
- 🇵🇱
Pulamgen Investigational Site, Warszawa, Poland
🇺🇸Pulmagen Investgational Site, Woodway, Texas, United States
🇺🇸Pulmagen Investigatinal Site, Clemmons, North Carolina, United States
Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Cantonal Hosptal, Baselland
- Target Recruit Count
- 17
- Registration Number
- NCT01725360
- Locations
- 🇨🇭
University Hospital Bern, Bern, Switzerland
The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 72
- Registration Number
- NCT01717625
- Locations
- 🇰🇷
Ajou university medical center, Suwon, Woncheon-dong, Yeongtong-gu,, Korea, Republic of
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
- Conditions
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT01702701
- Locations
- 🇺🇸
GI Associates, Milwaukee, Wisconsin, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 36
- Registration Number
- NCT01659892
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01659931
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.